Navigation Links
Thera Max® Cold and Flu Brand Receives Great Benefits from Its Ongoing Social Media Marketing Awareness Program

NEW YORK, Feb. 29, 2012 /PRNewswire/ -- TheraBiogen, Inc. (OTC BB: TRAB), a manufacturer and distributor of homeopathic  nasal sprays for aiding in the relief of allergies, cold and flu symptoms and migraine headaches, announced today the benefits its Thera Max® Cold and Flu brand is receiving through the ongoing Social Media campaign. 

The Company is taking its new homeopathic product, Thera Max® Cold and Flu into the social media arena in a very aggressive fashion. The campaign was launched on a billboard in Times Square, with interview testimonials posted on YouTube and receiving over 40,000 views to date. 

Additionally, CEO Kelly Hickel, has begun a radio media tour that has attracted editorial interest and the company believes that a number of other opportunities will arise from these efforts.  In October, the product was distributed to two large retail pharmacy chains and the Company intends to build upon this momentum.

Thera Max® offers a better alternative to cold and flu medications because it doesn't contain Zinc, which has been shown to cause adverse side-effects especially with nasal sprays.  Thera Max® Cold and Flu is an all-natural, non-addictive, over the counter cold and flu relief agent which aids in relief to cold and flu sufferers.

TheraBiogen, Inc., creator of TheraMax® Cold and Flu has a pipeline of products under development, including allergy, sore throat and migraine remedies. The growing interest in safe, homeopathic products is driving the continued development of the TheraBiogen lineup.

The product is currently sold in over 12,000 locations including Food Lion and various other retailers.  With the addition of the two large retailers, the Company intends to become a leading competitor in the world of over the counter medications for cold and flu symptoms.

The product is a homeopathic product of ingredients pre- approved on the HPUS website. Independent studies suggest the product aids in the temporary relief of common cold and flu ailments such as sneezing, runny nose, itch-watery eyes, nasal congestion and sinus pressure and can aid in the prevention if used correctly.

Flu commercials and Times Square videos may be viewed on the Thera Max® YouTube page at

Thera Max® Cold and Flu is an all-natural, non-zinc, non-addictive, over-the-counter cold and flu relief agent.  Over 50 million Americans contract the flu each year and consumer demand for a homeopathic, non-zinc remedy is a 2.5 billion dollar market according to research studies.

Thera Max® is available for purchase in over twelve thousand locations including Rite-Aid, Food Lion, Hannaford Supermarkets, Discount Drug Marts and Big Y Supermarkets as well as two of the three largest drug retailers.  For more information on Thera Max® visit our website at, our Facebook page at!/TheraMaxNasalSpray  or follow us on Twitter at

 About TheraBiogen, Inc.TheraBiogen is a manufacturer and distributor of homeopathic nasal sprays for aiding in the relief of allergies, cold and flu symptoms and migraine headaches. The products are made from natural, homeopathic ingredients and contain no zinc, which has been identified as potentially causing nasal problems in other similar products on the market. For further information please visit

Safe Harbor Statement

This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21 E of the Securities Exchange Act of 1934, as amended. Investors are cautioned that these forward-looking statements involve uncertainties and risk that could cause actual performance and results of operations to differ materially from those anticipated. These risks are set forth in the Company's most recently filed form 10-K and Form 10-Q reports. TheraBiogen, Inc. assumes no obligation to update the statements contained in this release except as required by applicable securities laws disclosure rules.Company Contact:Public Relations Contact:Investor Contact:TheraBiogen, Inc.

Megan Megale

Boutcher & BoutcherKelly T. Hickel, CEO

Megale Public Relations 

Aimee Boutcher732-294-8705


SOURCE TheraBiogen, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Nektar Therapeutics Announces Agreement to Sell CIMZIA® and MIRCERA® Royalties to Royalty Pharma for $124 Million
2. Varian Medical Systems Receives FDA 510(k) Clearance for Use of Transponder to Monitor Motion During Radiotherapy Anywhere in Body
3. New Therapy Program Allows Doctors to Prescribe Computer Games on iPad to Treat Visual Impairment
4. JARVIK HEART Announces FDA Conditional Approval of Trial Using the Jarvik 2000® Heart for Destination Therapy
5. Octapharma USA Submits BLA for octaplasLG®, a Therapy Targeting Adverse Transfusion Events
6. Generex Subsidiary Antigen Express to Present at Prestigious Cancer Immunotherapy Summit
7. Ameritox Supports New Expert Consensus Recommendations For Patients on Long-Term Opioid Therapy
8. Study Links the Risk of Hypogonadism in Men to Long Acting Opioids in Patients Using Daily Opioid Therapy for Chronic Noncancer Pain
9. Brainlab Partners With Radion to Integrate VoyantLink Image Sharing Into One Streamlined Solution for Radiation Therapy Centers
10. Anthera Pharmaceuticals to Present at the Citi Global Health Care Conference
11. Halozyme Therapeutics to Present at the CITI 2012 Global Healthcare Conference
Post Your Comments:
(Date:12/1/2015)... SAN FRANCISCO , Dec. 1, 2015  InCarda ... the development and commercialization of therapies for cardiovascular conditions ... established a subsidiary business in Australia ... clinical trial in Australia in ... with leading investigators and medical centers in ...
(Date:12/1/2015)... and TELTOW, Germany , December ... (SMI) , a leading global manufacturer of eye and ... has included SMI remote eye trackers as a ... healthcare providers assess concussions, eye sight, and medical and ... -oem technology is part of SMI,s mass-market-ready eye tracking ...
(Date:12/1/2015)... -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced ... 2016 as the ex-distribution date for Ampio,s previously announced ... Stock of Aytu BioScience, Inc. As announced, Ampio will ... every five (5) shares of Ampio Common Stock owned ... date will be January 4, 2016. ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... Lutronic, a leading innovator of aesthetic ... addition to the devices for sale in the United States. Clarity is a ... 1064 nm Nd:YAG lasers, into a single platform that is easy to own and ...
(Date:12/1/2015)... ... ... With FCPX Overlay: Grit , users can apply a grit effect ... truly endless, all with a click of a mouse. Each user has full control ... of field and more, all within Final Cut Pro X. , With FCPX Overlay: ...
(Date:11/30/2015)... India (PRWEB) , ... November 30, 2015 , ... ... dental search engine optimization companies, announced today that it has officially launched a ... Third Molar SEO, explained that his company’s new website clearly outlines the benefits ...
(Date:11/30/2015)... ... 2015 , ... The National Association of Professional Women (NAPW) honors ... Year Circle. She is recognized with this prestigious distinction for leadership in estate sales ... more than 850,000 members and over 200 operating Local Chapters. , “I’m pleased to ...
(Date:11/30/2015)... ... November 30, 2015 , ... Until now, the St. ... in the MOMS (Management of Myelomeningocele Study) trial. One of these exclusion criteria was ... a BMI of 18.5 to 24.9 is considered normal, 25 - 29.9 is overweight ...
Breaking Medicine News(10 mins):